Adverse effects of bevacizumab in metastatic colorectal cancer : a case report and literature review
Journal | Volume 82 - 2019 |
Issue | Fasc.2 - Case reports |
Author(s) | E. Willems, L. Gerne, C. George, M. D'Hondt |
Full article |
VIEW FREE PDF |
(1) Department of Digestive and Hepatobiliary/Pancreatic Surgery, AZ Groeninge Kortrijk, Belgium ; (2) Department of Gastro-enterology, AZ Groeninge Kortrijk, Belgium |
Colorectal cancer is one of the most frequently diagnosed malignancies worldwide. One of the most important developments in the management of metastatic colorectal cancer is targeted therapy. Bevacizumab, a monoclonal antibody inhibiting VEGF induced angiogenesis, has been accepted as safe and efficient in the treatment of metastatic colorectal cancer for more than a decade. Addition of bevacizumab to fluorouracil-based chemotherapy is also associated with severe adverse events. We present a case of bevacizumab-induced bowel ischaemia associated with gastro- intestinal haemorrhage. (Acta gastroenterol. belg., 2019, 82, 322- 325). |
© Acta Gastro-Enterologica Belgica. PMID 31314196 |